QTTB Stock — Q32 Bio Inc.: Cash, EV, Pipeline

Share price

$10.54

Market cap

$313.8M

Cash

$293.9M

Enterprise value

$19.9M

Balance sheet

Cash	$293.9M
Debt	$0.0M
Net cash	$293.9M
Enterprise value	$19.9M
Basic shares	23.7M shares
Fully diluted shares	37.3M shares
Fully diluted market cap	$392.8M
Cash per share	$12.40

Cash figures as of 2026-07-16. Database snapshot: 2026-09-21.

Price history

Loading QTTB daily closes…

Loading price history…

Pipeline assets

bempikibart

Phase 2 · Active Modality: monoclonal antibody (fully human)

Aliases ADX-914

Target IL-7Rα

Indications

alopecia areata (AA) (Phase 2)
atopic dermatitis (AD) (Phase 2)

Catalysts

— July 2026
— not dated

Status note Fully human anti-IL-7Rα antibody that re-regulates adaptive immune function. Completed SIGNAL-AA Part A and SIGNAL-AD Phase 2a trials (toplines Dec 2024); company chose to advance AA. SIGNAL-AA Part B dosed first patient April 2025; 36-week topline results announced July 2026. Planned registration-directed program in AA.

ADX-097

Phase 2 · Active Modality: monoclonal antibody fusion protein (anti-C3d)

Target C3d

Status note Phase 2 asset from proprietary tissue-targeted complement inhibitor platform; humanized anti-C3d mAb fusion protein that completed Phase 1 clinical trials. Indication for Phase 2 not stated in excerpts.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	ADX-914
Lead indication	Atopic Dermatitis
Lead phase	Phase 2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05509023	Phase 2	Active, not recruiting	Sponsor	Q32 Bio Inc.	—	Atopic Dermatitis	—
NCT06018428	Phase 2	Active, not recruiting	Sponsor	Q32 Bio Inc.	—	Alopecia Areata	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Q32 Bio Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	4,127,987	+1,875,000	1.00%	2026-08-14
Logos Global Management	800,000	+800,000	0.44%	2026-08-14
Ikarian Capital	430,000	+430,000	0.90%	2026-08-14
ADAR1 Capital Management	0	-35,000	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

QTTB — Q32 Bio Inc.